| Literature DB >> 28558772 |
Zhou Tong1, Lulu Liu1, Yi Zheng1, Weiqin Jiang1, Peng Zhao1,2, Weijia Fang1,2, Weilin Wang3,4,5.
Abstract
BACKGROUND: Neutrophil-to-lymphocyte ratio (NLR) is one of the systemic inflammation markers, which has prognostic values in many types of tumor. However, hardly any research has reported the relationship between NLR and pancreatic neuroendocrine tumors (PanNETs). In this study, we aimed to evaluate the predictive value of the preoperative peripheral blood NLR on the clinical outcomes in patients of resectable PanNETs.Entities:
Keywords: Lymph node metastasis; Neutrophil-to-lymphocyte ratio; Pancreatic neuroendocrine tumors; Recurrence-free survival
Mesh:
Year: 2017 PMID: 28558772 PMCID: PMC5450407 DOI: 10.1186/s12957-017-1169-5
Source DB: PubMed Journal: World J Surg Oncol ISSN: 1477-7819 Impact factor: 2.754
Patient characteristics
| Characteristics | Patients (cases (%)) |
|---|---|
| Gender | |
| Male | 39 (41.1) |
| Female | 56 (58.9) |
| Age, years | 54.4 ± 12.1 |
| TNM staging of ENETS in 2006 | |
| T1 | 34 (35.8) |
| T2 | 28 (29.5) |
| T3 | 21 (22.1) |
| T4 | 12 (12.6) |
| N0 | 80 (84.2) |
| N1 | 15 (15.8) |
| M0 | 80 (84.2) |
| M1 | 15 (15.8) |
| Grading classifications of WHO 2010 | |
| NET G1 | 52 (54.7) |
| NET G2 | 32 (33.7) |
| NEC G3 | 11 (11.6) |
| Tumor thrombus | |
| Yes | 6 (6.3) |
| No | 89 (93.7) |
| Surgical resection | |
| Radical | 89 (93.7) |
| Nonradical | 6 (6.3) |
| Functioning tumor | |
| Yes | 21 (22.1) |
| No | 74 (77.9) |
| Blood loss volume, ml | 312.8 ± 661.2 |
| Operation duration, min | 302.0 ± 158.0 |
| Surgical approaches | |
| Distal pancreatectomy | 47 (49.5) |
| Local resection of pancreatic tumor | 19 (20.0) |
| Pancreaticoduodenectomy | 27 (28.4) |
| Total pancreatectomy | 2 (2.1) |
NET neuroendocrine tumor, NEC neuroendocrine carcinoma
Preoperative NLR and clinical parameters
| Variables | Number | NLR (mean ± SD) |
|
|---|---|---|---|
| Gender | |||
| Male | 39 | 2.165 ± 0.980 | 0.908 |
| Female | 56 | 2.134 ± 1.474 | |
| Age | |||
| ≤60 | 60 | 2.102 ± 1.335 | 0.659 |
| >60 | 35 | 2.224 ± 1.218 | |
| TNM staging of ENETS in 2006 | |||
| T1, T2 | 62 | 1.909 ± 0.843 | 0.044 |
| T3, T4 | 33 | 2.594 ± 1.790 | |
| N0 | 80 | 1.912 ± 0.836 | <0.001 |
| N1 | 15 | 3.399 ± 2.282 | |
| M0 | 80 | 2.094 ± 1.290 | 0.361 |
| M1 | 15 | 2.427 ± 1.287 | |
| New grading classifications of WHO in 2010 | |||
| NET G1 | 52 | 1.862 ± 0.746 | 0.015 |
| NET G2 | 32 | 2.305 ± 1.597 | |
| NEC G3 | 11 | 3.031 ± 1.868 | |
| Tumor thrombus | |||
| Yes | 6 | 3.703 ± 1.573 | 0.002 |
| No | 89 | 2.042 ± 1.207 | |
| Functioning tumor | |||
| Yes | 21 | 2.049 ± 0.874 | 0.697 |
| No | 74 | 2.174 ± 1.387 | |
| AFP | |||
| Normal | 91 | 2.171 ± 1.308 | 0.384 |
| Abnormal | 4 | 1.594 ± 0.521 | |
| CA199 | |||
| Normal | 93 | 2.163 ± 1.300 | 0.396 |
| Abnormal | 2 | 1.378 ± 0.251 | |
| CEA | |||
| Normal | 91 | 2.159 ± 1.312 | 0.665 |
| Abnormal | 4 | 1.872 ± 0.444 | |
| CA125 | |||
| Normal | 92 | 2.147 ± 1.300 | 0.979 |
| Abnormal | 3 | 2.128 ± 1.067 | |
NET neuroendocrine tumor, NEC neuroendocrine carcinoma, AFP alpha-fetoprotein, CA199 carbohydrate antigen 199, CEA carcinoembryonic antigen, CA125 carbohydrate antigen 125
Fig. 1ROC curve for NLR to a lymph node metastasis and b recurrence-free survival. Arrows indicate optimal cutoff values
Univariate and multivariate analyses of clinical characteristics according to lymph node metastasis
| Characteristics | Univariate | Multivariate | ||
|---|---|---|---|---|
| HR (CI 95%) |
| HR (CI 95%) |
| |
| Gender | ||||
| Male | 2.5 (0.809, 7.722) | 0.111 | ||
| Female | ||||
| Age | ||||
| Age ≤60 | 0.833 (0.260, 2.672) | 0.759 | ||
| Age >60 | ||||
| TNM staging of ENETS in 2006 | ||||
| T1, T2 | 19.500 (4.047, 93.951) | <0.001 | 11.940 (2.098, 67.965) | 0.005 |
| T3, T4 | ||||
| New grading classifications of WHO in 2010 | ||||
| NET G1 + G2 | 16.625 (3.986, 69.349) | <0.001 | 10.378 (1.399, 77) | 0.022 |
| NEC G3 | ||||
| Tumor thrombus | ||||
| Yes | 14.182 (2.319, 86.74) | 0.004 | 0.603 (0.049, 7.429) | 0.693 |
| No | ||||
| AFP | ||||
| Normal | 1.008 (0.993, 1.023) | 0.317 | ||
| Abnormal | ||||
| CA199 | ||||
| Normal | 0.989 (0.938, 1.043) | 0.684 | ||
| Abnormal | ||||
| CEA | ||||
| Normal | 1.014 (0.687, 1.497) | 0.943 | ||
| Abnormal | ||||
| CA125 | ||||
| Normal | 1.033 (0.969, 1.102) | 0.320 | ||
| Abnormal | ||||
| NLR ≤2.056 | 7.429 (1.934, 28.540) | 0.003 | 6.740 (1.298, 34.998) | 0.023 |
| NLR >2.056 | ||||
| Functional tumor | ||||
| Yes | 0.214 (0.026, 1.734) | 0.149 | ||
| No | ||||
NET neuroendocrine tumor, NEC neuroendocrine carcinoma, AFP alpha-fetoprotein; CA199 carbohydrate antigen 199, CEA carcinoembryonic antigen, CA125 carbohydrate antigen 125
Fig. 2A nomogram to predict the risk of LN metastasis of PanNETs after operation. In this model, patients with high points are more likely to obtain LN metastasis
Fig. 3The ROC curve of the multivariate logistic regression model. The ROC curve illustrated integrated factors have an AUC of 0.885 (95% CI 0.783–0.987), which is larger than using the individual factors of NLR (0.725, 95% CI 0.591–0.859), T stage (0.808, 95% CI 0.693–0.924), and grade (0.708, 95% CI 0.541–0.876)
Fig. 4Calibration plot of nomogram. The dashed line indicates the ideal nomogram in which predicted and actual probabilities were perfectly identical. The dotted line indicates actual nomogram performance. The solid line presents the bootstrap corrected performance of our nomogram. The calibration plot illustrates a good predictive accuracy
Fig. 5Kaplan–Meier recurrence-free survival curves for the patients with PanNETs after resection. The survival curves show that the patients with high NLR decreased significantly as compared with those of low NLR
Fig. 6Kaplan–Meier recurrence-free survival curves for the patients with PanNETs after resection. The survival curves show that the patients with LN positive decreased significantly as compared with those of LN negative